Adding metformin to insulin therapy in patients with type 2 diabetes does not impact long-term outcomes

The addition of metformin to insulin therapy in patients with type 2 diabetes does not significantly impact all-cause or cardiovascular mortality, although the combination reduced hemoglobin A1C values, weight gain, and insulin doses, a recent study found. Combining metformin to insulin also may increase the risk of hypoglycemia.

According to the World Diabetes Foundation, India has the world’s largest diabetic population, estimated at 50.8 million people. Worldwide, diabetes is one of the leading causes of premature illness and death.

Researchers from Denmark conducted a systematic review and meta-analysis that evaluated the efficacy and safety of combining the oral antihyperglycemic agent metformin with insulin compared with...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Diabetes, Non-Communicable Disease, Pharmacology, Primary Care and tagged , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.